Full-Time

Investor – AI Tools

Posted on 9/4/2025

Samsung Next

Samsung Next

201-500 employees

Venture funding for AI and healthtech

Compensation Overview

$175k - $195k/yr

Mountain View, CA, USA

Hybrid

Category
Data & Analytics (2)
,
Required Skills
LLM
Python
JavaScript
TypeScript
Requirements
  • Undergraduate degree in a technical discipline or experience in a technical role
  • Highly successful 2+ years of technical experience
  • Expertise in building AI-powered tools that amplify human decision-making with demonstrated track record
  • Have strong coding skills (Python, JavaScript/TypeScript, or similar) and experience with LLM APIs, embeddings, and retrieval systems
  • Adept at developing and leveraging strong professional relationships
  • Love technology markets - both the underlying technology and the business strategies and outcomes
  • Displays high EQ and is a team oriented contributor
  • Demonstrates outstanding analytical and communication skills both written and verbal - able to simplify the complex and provide pointed insights
Responsibilities
  • Foundation: Get the Data into Shape: Investor Update Ingestion Pipeline – Build systems to collect investor updates (emails, PDFs, Notion docs, Google Drive folders), apply OCR + parsing, and tag each update with company name, sector, stage, date, funding, and geography
  • Portfolio Metadata Enrichment – Pull in public data from Crunchbase, PitchBook, LinkedIn, etc., to fill in missing details (founder background, funding history, employee count)
  • Basic Search & Retrieval System – Set up a RAG tool so the team can query portfolio data in natural language
  • Early Insights Dashboard (MVP) – Provide basic metrics on distribution by sector, stage, geography, and funding rounds over time
  • Trend Heatmap – Apply NLP to extract common themes, tech mentions, and challenges from investor updates, and visualize trends over time
  • Success/Failure Pattern Analysis – Identify shared characteristics among top-performing companies and those struggling or shutting down
  • Samsung Collaboration Impact Tracker – Link internal engagement (introductions, pilots, technical help) with measurable outcomes for startups
  • Founder Playbook Extractor – Build tools to extract tactical lessons from founder updates
  • Startup-to-Business-Unit Mapping Engine – Develop a tagging/matching system that aligns portfolio companies to Samsung’s core and adjacent businesses
  • Competitive Intelligence Layer – Flag when a portfolio startup’s moves overlap with competitor activity
  • Startup Readiness Scores – Score each company on tech maturity, scalability potential, and fit for corporate partnership
  • Unified Portfolio CRM – Link startup data with Samsung’s internal BD/partnership CRM

Samsung Next funds and supports bold founders building transformative technologies in AI, intelligent machines, healthtech, consumer services, and frontier tech. It operates as Samsung’s corporate venture arm, providing capital, mentorship, and hands-on support to help startups scale, with access to Samsung’s resources, customers, and global network. The product is not a consumer app but a service for startups: funding combined with operational help, go-to-market support, and strategic partnerships that leverage Samsung’s platforms. The company differentiates itself through its tight integration with a global hardware and consumer electronics giant, enabling portfolio companies to pilot, validate, and deploy at scale within Samsung’s ecosystem. Its goal is to identify and back ambitious founders whose technologies can transform industries and eventually reach widespread adoption through Samsung’s reach and infrastructure.

Company Size

201-500

Company Stage

N/A

Total Funding

$6.4B

Headquarters

Mountain View, California

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • AI agent proliferation drives sustained demand for specialized inference infrastructure through 2027.
  • Beacon Biosignals and Nucleus Genomics capture preventive health market exceeding $100 billion.
  • World models enable robotics, gaming, and defense applications with massive TAM expansion.

What critics are saying

  • DeepInfra and Parasail cannibalize each other; Samsung Next forced to choose winner.
  • OpenAI, Google, Meta undercut inference pricing 30-40%, collapsing portfolio unit economics.
  • Nucleus Genomics fails securing payer contracts by Q4 2026; business model collapses.

What makes Samsung Next unique

  • Samsung Next backs AI inference infrastructure leaders processing trillions tokens weekly.
  • Portfolio spans biotech diagnostics, world models, and genomics with strategic Samsung integration.
  • Invests in purpose-built, cost-optimized platforms competing against generalist cloud providers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Flexible Work Hours

Company News

Yahoo Finance
Apr 6th, 2026
Beacon Biosignals upsizes Series B to $97M to advance at-home EEG brain health diagnostics

Beacon Biosignals has extended its Series B financing to $97 million, bringing total funding to over $132 million. The upsized round includes new investors JSL Health, Palo Santo VC, Kicker Ventures and Samsung Next. The Boston-based company combines FDA-cleared wearable EEG technology with AI to capture and analyse brain data for neurology, psychiatry and sleep medicine applications. The additional capital will accelerate Beacon's development of at-home EEG and advanced analytics for diagnostics, clinical trials and precision medicine. The original $86 million Series B was led by healthcare and technology investors including Innoviva, GV, S32, Catalio Capital Management, General Catalyst, Logos Capital, Casdin Capital and Indicator Ventures. The platform provides clinicians and biopharma partners with objective measures of brain function.

Business Wire
Mar 26th, 2026
Xona Closes $170M Series C to Lead Next Era of Global Navigation

Xona, building the next era of global positioning, navigation, and timing (PNT) infrastructure, today announced $170 million Series C funding.

FinancialContent
Mar 26th, 2026
Xona raises $170M Series C to build commercial GPS upgrade with new California factory

Xona, a commercial space company building positioning, navigation and timing infrastructure, has raised $170 million in an oversubscribed Series C round led by Mohari Ventures Natural Capital. Participants include Craft Ventures, ICONIQ, Woven Capital, NGP Capital, Samsung Next and Hexagon. The company is developing Pulsar, a navigation service broadcast from low Earth orbit satellites with stronger signals and military-grade encryption, compatible with existing GPS devices. Over a dozen commercial receiver partners are tracking Pulsar signals, with early customers expected to benefit from coverage by 2027. The funding will accelerate constellation deployment and manufacturing scale-up at Xona's new Burlingame, California factory. At full production, the company aims to manufacture more navigation satellites weekly than the US currently produces annually, deploying its 258-satellite constellation within a few years.

The Tech Buzz
Mar 17th, 2026
Samsung Ventures Backs Grid Beyond's Power Grid Tech

Island startup Grid Beyond lands Samsung investment for grid-balancing software

Femtech Insider
Feb 25th, 2026
Samsung Next invests in Nucleus Genomics' $499 whole-genome sequencing platform

Nucleus Genomics, a clinical-grade whole-genome sequencing platform, has received a strategic investment from Samsung Next, following a $14 million Series A led by Founders Fund and Seven Seven Six. The company offers a $499 physician-ordered test sequencing approximately 100% of a patient's DNA, covering over 2,000 diseases through a CLIA-certified, CAP-accredited US lab. Nucleus recently acquired Cambrean, an AI-powered wearable health platform, to combine continuous biometric data with genetic baselines. Samsung Next cited the company's scientific rigour and potential as a genetic baseline layer for wearables and health sensors. The company initially drew attention with its Nucleus Embryo product, allowing IVF patients to compare embryos based on traits including appearance and cognitive ability. Nucleus now appears to be repositioning as a broader preventive health genomics platform.

INACTIVE